06:39:25 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-06-03 Bokslutskommuniké 2025
2025-03-03 Kvartalsrapport 2025-Q3
2024-12-04 Kvartalsrapport 2025-Q2
2024-09-25 Årsstämma 2025
2024-08-29 Kvartalsrapport 2025-Q1
2024-05-30 Bokslutskommuniké 2024
2024-02-29 Kvartalsrapport 2024-Q3
2023-12-04 Kvartalsrapport 2024-Q2
2023-10-04 Ordinarie utdelning INTEG B 0.00 SEK
2023-09-27 Årsstämma 2024
2023-08-31 Kvartalsrapport 2024-Q1
2023-06-08 Bokslutskommuniké 2023
2023-03-01 Kvartalsrapport 2023-Q3
2022-12-01 Kvartalsrapport 2023-Q2
2022-10-03 Ordinarie utdelning INTEG B 0.00 SEK
2022-09-28 Årsstämma 2023
2022-08-31 Kvartalsrapport 2023-Q1
2022-06-10 Bokslutskommuniké 2022
2022-03-02 Kvartalsrapport 2022-Q3
2021-12-02 Kvartalsrapport 2022-Q2
2021-09-09 Ordinarie utdelning INTEG B 0.00 SEK
2021-09-02 Kvartalsrapport 2022-Q1
2021-05-31 Bokslutskommuniké 2021
2021-03-03 Kvartalsrapport 2021-Q3
2020-12-02 Kvartalsrapport 2021-Q2
2020-09-30 Årsstämma 2021
2020-09-09 Ordinarie utdelning INTEG B 0.00 SEK
2020-08-24 Kvartalsrapport 2021-Q1
2020-06-08 Bokslutskommuniké 2020
2020-04-20 Extra Bolagsstämma 2020
2020-03-02 Kvartalsrapport 2020-Q3
2019-12-02 Kvartalsrapport 2020-Q2
2019-09-30 Årsstämma 2020
2019-09-25 Ordinarie utdelning INTEG B 0.00 SEK
2019-09-02 Kvartalsrapport 2020-Q1
2019-06-10 Bokslutskommuniké 2019
2019-03-04 Kvartalsrapport 2019-Q3
2018-12-17 Kvartalsrapport 2019-Q2
2018-09-25 Ordinarie utdelning INTEG B 0.00 SEK
2018-09-24 Årsstämma 2019
2018-09-24 Kvartalsrapport 2019-Q1
2018-06-25 Bokslutskommuniké 2018
2018-03-26 Kvartalsrapport 2018-Q3
2017-12-18 Kvartalsrapport 2018-Q2
2017-09-25 Årsstämma 2018
2017-09-25 Kvartalsrapport 2018-Q1
2017-06-30 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Integrum är verksamt inom medicinteknik. Idag utvecklar bolaget system för skelettförankrade proteser baserat på det framtagna OPRA-implantatsystemet, som senare vidaresäljs till sjukhus världen över. Implantatet sätts på patientens ben med hjälp utav titanskruvar och antas förbättra livet för en stor del patienter med amputation. Bolaget grundades 1998 och har sitt huvudkontor i Mölndal.
2023-05-11 13:52:20

Mölndal, Sweden - May 11, 2023 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that Scott Flora has been appointed as an adjunct board member effective immediately. Scott Flora brings vast and extensive competence to the company as Integrum is reinforcing the company's position as a leader of osseointegrated implant systems.

Scott Flora has over 40 years of experience in strategic and leadership roles in the healthcare sector, particularly in surgical devices, and has held prominent leadership positions at companies including Covidien and Smith & Nephew. He is currently Chairman of the Board at Palliare Ltd and a board member at CytoVeris and New View Surgical. Scott Flora also serves as Strategic Advisor to CareSyntax, MiCarePath, and Integrum. He has previously held several leading positions roles as President and CEO of Invuity (acquired by Stryker), Executive Director of Conventus Orthopaedics, President and CEO of OmniGuide Surgical, President of Covidien's Surgical Device Group, President of Smith& Nephew Orthopedic Reconstruction and General Manager at Smith&Nephew Trauma. Scott Flora has also served on the company boards of Invuity (acquired by Stryker), MAKO Surgical, and Tengion.

"We are excited to have Scott Flora joining our Board as an adjunct board member, prolonging his commitment to the company from his current role as a Strategic advisor. He brings valuable strategic knowledge to the company in eventful times as we are expanding our business around the globe," said Bengt Sjöholm, chairman of the board at Integrum.

"Integrum is well positioned and has a unique offer driving the innovation of osseointegrated implant systems. I am thrilled to take a seat on the board and hope to bring strategic insights that help strengthen the company's commercial strategy and grow the market," said Scott Flora, adjunct board member of Integrum.